Combined CAR-T Therapy and Radiotherapy in Non-Hodgkin Lymphoma: Real-World Data Files

This retrospective cohort study utilized electronic health records from the TriNetX database. A total of 502 NHL patients were included, categorized into CAR-T R+ (receiving CAR-T and radiotherapy) and CAR-T R- (receiving CAR-T and chemotherapy only) groups, balanced through propensity score matching. The primary outcome was four-year mortality risk. Secondary outcomes included emergency visits, organ failure, sepsis, cardiovascular events, inflammation over four years, and acute reactions (Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)) measured over one month.